Descriptive epidemiology of ovarian cancer in the United States, 1992-1997

Cancer

Volumn 97, Issue 10 SUPPL., 2003, Pages 2615-2630

  Goodman, Marc T ^a   Howe, Holly L ^b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b N Amer Assoc Ctrl Cancer Regis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; DISEASE SEVERITY; ETHNOLOGY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; OVARY CANCER; PRIORITY JOURNAL; PUBLICATION; RACE DIFFERENCE; SOCIOECONOMICS; UNITED STATES;

EID: 0037629072     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11339     Document Type: Article

References (69)

1. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ. 1993;121:1-806.
2. Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat. 2000; 5:221-231.
3. Ries LAG, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
4. Howe HL, Wingo PA, Thun MI, Ries LAG, Rosenberg H, Edwards BK. Annual report to the nation on the status of cancer, 1973-1998, featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93:824-842.
5. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER cancer statistics review, 1973-1997. NIH Pub. No. 00-2789. Bethesda, MD: National Cancer Institute, 2000.
6. American Cancer Society. Cancer facts and figures, 2001. New York: American Cancer Society, Inc., 2001.
7. Weiss NS, Cook LS, Farrow DC, Rosenblatt KA. Ovarian cancer. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press, 1996:1040-1057.
8. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):2631-2642.
9. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 1996;144:363-372.
10. Goodman MT, Correa CN, Tung K-H, et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):2648-2659.
11. Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):2676-2685.
12. Young JL, Wu XC, Roffers SD, Howe HL, Correa CN, Weinstein R. Ovarian cancer in children and young adults in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):2694-2700.
13. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774-1786.
14. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inference regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-721.
15. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet. 1971;2:163.
16. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet. 1979;2:170-173.
17. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G. Risk factors for epithelial ovarian tumors in Italy. Am J Epidemiol. 1982;115:714-719.
18. Wu ML, Whittemore AS, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 1988;128:1216-1227.
19. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981;114:398-405.
20. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91: 1459-1467.
21. Stadel BV. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol. 1975;123:772-774.
22. Zajicek J. Prevention of ovarian cystomas by inhibition of ovulation: a new concept. J Reprod Med. 1978;20:114.
23. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome13q12-13. Science. 1994;265:2088-2090.
24. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
25. Vachon CM, Mink PJ, Janney CA, et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology. 2002;13:66-71.
26. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1997;89:932-938.
27. Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1998;90:1729-1734.
28. Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 1994;52:232-236.
29. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052-7056.
30. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-4091.
31. Tokuoka S, Kawai K, Shimizu Y, et al. Malignant and benign ovarian neoplasms among atomic bomb survivors, Hiroshima and Nagasaki, 1950-80. J Natl Cancer Inst. 1987;79: 47-57.
32. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992; 80:19-26.
33. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92:472-479.
34. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US casecontrol studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136:1184-1203.
35. Kushi LH, Mink PJ, Folsom AR, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol. 1999;149:21-31.
36. Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet. 1989;2:66-71.
37. Scully RE. Influence of origin of ovarian cancer on efficacy of screening. Lancet. 2000;355:1028-1029.
38. Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumors. J Natl Cancer Inst. 1987;78:71-74.
39. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US casecontrol studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1204-1211.
40. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol. 2001;11:568-574.
41. Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001;83:575-585.
42. Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 1997;80:816-826.
43. Averette HE, Janicek MF, Menck HR. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1096-1103.
44. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynecol. 1998;105:1136-1147.
45. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999; 353:1207-1210.
46. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000; 21(6 Suppl):251S-272S.
47. Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology. 1998;208:103-110.
48. McGuire V, Herrinton L, Whittemore AS. Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization. Epidemiology. 2002;13:231-234.
49. Centers for Disease Control and Prevention (CDC). Behavioral risk factor surveillance system online prevalence data, 1995-2000. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2000. Available from URL: http://www.cdc.gov/brfss/ [accessed 12 March 2003].
50. Roffers SD, Wu XC, Johnson CH, Correa CN. Incidence of extraovarian primary cancers in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):2643-2647.
51. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16:791-801.
52. Chen VW, Howe HL, Wu XC, Hotes J, Correa C, editors. Cancer in North America, 1993-1997. Volume 1: incidence. Sacramento, CA: North American Association of Central Cancer Registries, 2000.
53. Percy C, Van Holten V, Muir C, editors. International classification of disease for oncology, 2nd edition. Geneva: World Health Organization, 1990.
54. Shambaugh EM, Weiss MA, editors. Summary staging guide: cancer surveillance, epidemiology, and end results reporting, SEER program April 1977. NIH Pub. No. 98-2313. Bethesda, MD: National Institutes of Health, National Cancer Institute, 1977.
55. Scully RE, Salazar H. Problems in the histological typing of ovarian cancer. In: Stalsberg H, editor. An international survey of distributions of histological types of tumours of the testis and ovary. International Union Against Cancer Technical Report Series, volume 75. Geneva: International Union Against Cancer, 1983:125-135.
56. Tyler CW Jr., Lee NC, Robboy SJ, et al. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol. 1991;164:65-70.
57. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol. 2002;84:36-42.
58. West D, O'Malley C, Unger-Hu K. The NAACCR race and ethnicity identifier assessment project. Presented at: the NAACCR Collaborative Research Working Group, June 8, 2001, Miami, Florida.
59. Trapido E. NAACCR uniform data standards committee, subcommittee on methodologic issues of measuring cancer among hispanics. "Final report of Atlanta symposium" (held January 19-20, 1996). Available from URL: http://www. naaccr.org/Stats/EpiReports.html#Race [accessed 31 October 2001].
60. Kolonel LN, Goodman MT. Racial variation in cancer: factor artifact? J Natl Cancer Inst. 1992;84:916-917.
61. Rosenberg HM, Maurer JD, Sorlie PD, et al. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. Vital and health statistics, Series 2, No. 128. Hyattsville, MD: National Center for Health Statistics, 1999.
62. Poe GS, Powell-Griner E, McLaughlin JK, Placek PJ, Thompson GB, Robinson K. Comparability of the death certificate and the 1986 national mortality follow-back survey. National Center for Health Statistics. Vital and Health Stat. 1993;2(118).
63. Hogan H. The 1990 post-enumeration survey: operations and results. J Am Stat Assoc. 1993;88:1047-1060.
64. Howe HL, Weinstein R, Hotes J, Kohler B, Roffers SD, Goodman MT. Multiple primary cancers of the ovary in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):000-000.
65. Howe HL, Tung K-H, Coughlin S, Jean-Baptiste R, Hotes J. Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):000-000.
66. Hall HI, Tung K-H, Hotes J, Logan P. Regional variations in ovarian cancer incidence in the United States, 1992-1997. Cancer. 2003;97(10 Suppl):000-000.
67. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989;96:889-892.
68. American Joint Committee on Cancer. Ovary. In: Fleming ID, Cooper IS, Henson DE, et al. AJCC manual for staging of cancer, 5th edition. Philadelphia: Lippincott-Raven, 1997: 201-206.
69. Parkin DM, Shanmugaratnam K, Sobin L, Ferlay J, Whelan SL. Histological groups. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents, volume VII. Lyon: International Agency for Research on Cancer; 1997 Scientific Pub. No. 143:34-44.